Indium-111 octreotide scintigraphy in neurofibromatosis

Carlo L. Maini, Raffaele R. Cioffi, Anna Tofani, Rosa Sciuto, Maurizio Fontana, Carmine M. Carapella, Marcello Crecco

Research output: Contribution to journalArticlepeer-review


Scintigraphy with the radiolabelled somatostatin analogue indium-111-DTPA-D-Phe-l-octreotide has recently been proposed for the imaging of CNS neoplasms expressing somatostatin receptors. While meningiomas are imaged with high sensitivity, neurinomas do not take up octreotide owing to the lack of somatostatin receptors. Neurofibromatosis is a relatively uncommon disorder in which meningiomas and neurinomas often occur in the same patient. Differential diagnosis between these two tumours by computed tomography and magnetic resonance imaging can be difficult. This study reports on1 11In-octreotide scintigraphy in four patients with neurofibromatosis.11In-octreotide scintigraphy was shown to be very helpful in the in vivo differential diagnosis: all four meningiomas showed intense tracer uptake, while all 15 neurinomas were negative (P111In-octreotide is a useful diagnostic procedure in neurofibromatosis, complementing standard neuroradiological imaging procedures.

Original languageEnglish
Pages (from-to)201-206
Number of pages6
JournalEuropean Journal Of Nuclear Medicine
Issue number3
Publication statusPublished - Mar 1995


  • Indium-111 octreotide scintigraphy
  • Neurofibromatosis
  • Somatostatin receptors

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Indium-111 octreotide scintigraphy in neurofibromatosis'. Together they form a unique fingerprint.

Cite this